In the end, considering FGF21 roles in glucose and lipid metabolism and also in energy balance and according to its effects on NAFLD and NASH, FGF21 could be a potential biomarker for diagnosis of NAFLD and NASH and it might also be a target for the treatment of these conditions. Here, FGF21 is linked to metabolic dysfunction-associated steatohepatitis.